Condition (MeSH)
Leukemia, Promyelocytic, Acute
ClinicalTrials.gov lists 129 trials for Leukemia, Promyelocytic, Acute or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 19.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 more section with rows
129 of the 129 trials are tagged with Leukemia, Promyelocytic, Acute itself; the rest are tagged with a narrower condition beneath it.
When did Leukemia, Promyelocytic, Acute trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access)
Top of scale: 13
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2023 | 3 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2016 | 3 |
Showing 10 of 32 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 5 trials still running at the 2026-10-09 snapshot; registered median of 51 months across 87 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leukemia, Promyelocytic, Acute trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 33 |
| Phase 1/2 | 5 |
| Phase 2 | 40 |
| Phase 2/3 | 3 |
| Phase 3 | 16 |
| Phase 4 | 7 |
| Not applicable | 5 |
| Observational | 18 |
| Expanded access | 2 |
How many Leukemia, Promyelocytic, Acute trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 3 |
| Completed | 74 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leukemia, Promyelocytic, Acute trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 19 |
| Children's Oncology Group | 4 |
Which drugs are being tested for Leukemia, Promyelocytic, Acute? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Arsenic Trioxide | 25 |
| Cytoxan | 14 |
| Busulfan | 11 |
| MERCAPTOPURINE | 7 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| All-Trans Retinoid Acid(ATRA) | 24 |
| Cytarabine IT | 19 |
| HD- Methotrexate (MTX) | 13 |
| Idarubicina | 11 |
| Filgrastime (G-CSF) | 10 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Leukemia, Promyelocytic, Acute trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Platelets | 154 | 2 |
| Neutrophils | 150 | 1 |
| Leukocytes | 134 | 1 |
| Hemoglobin | 110 | 2 |
| Febrile neutropenia | 83 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Leukemia, Promyelocytic, Acute? (157)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Arsenic trioxide <i>versus</i> Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial. | Haematologica | 2025 | Yes |
| Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. | Cancer | 2025 | Yes |
| Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly diagnosed patients: impact and outcome. | Blood advances | 2025 | Yes |
| A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia. | Blood advances | 2025 | Yes |
| Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | Yes |
Showing 5 of 157 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Acute promyelocytic leukemia | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Acute promyelocytic leukemia | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Acute promyelocytic leukemia | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Acute promyelocytic leukemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Acute promyelocytic leukemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Acute promyelocytic leukemia | 520 | Exact | Orphadata Science knowledge files, Product 1 |
| Acute promyelocytic leukemia | 520 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.